Articles Published in 2012

Amgen, KPCB partner to create new spin-out biotech

Friday, October 26, 2012 02:43 PM

Amgen, a biotech based in Thousand Oaks, Calif., and Kleiner Perkins Caufield & Byers (KPCB), a venture capital firm, have created Atara Biotherapeutics, a new drug development company with a focus on innovative therapies for patients with chronic diseases in therapeutic areas including nephrology and oncology.

More... »

AstraZeneca, Ironwood announce linaclotide collaboration for China

Friday, October 26, 2012 02:20 PM

AstraZeneca, a global biopharmaceutical company, and Ironwood Pharmaceuticals, a Cambridge, Mass.-based entrepreneurial pharmaceutical company, have signed an agreement to co-develop and co-commercialize Ironwood’s linaclotide in China.

More... »

Premack joins Celtaxsys as chief technology officer

Friday, October 26, 2012 12:31 PM

Celtaxsys, a San Francisco-based, private biopharmaceutical company developing a new class of drugs to treat inflammatory disorders through innate immunity, has appointed life sciences technology expert, Brett A. Premack, Ph.D., as chief technology officer.

More... »

Shire’s Angus Russell to retire in 2013, Ornskov to succeed as CEO

Friday, October 26, 2012 12:07 PM

The board of directors of Shire, a global specialty biopharmaceutical company based in Ireland, has announced the retirement in 2013 of chief executive Angus Russell after 13 years with the company and 32 years in the pharmaceutical industry.

More... »

Thrasos secures $35M for THR-184 phase II program for acute kidney injury

Friday, October 26, 2012 11:39 AM

Thrasos Therapeutics, a Canadian clinical stage biotherapeutics company, has completed a $35 million financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).

More... »

arGEN-X appoints David Lacey to supervisory board

Friday, October 26, 2012 11:12 AM

arGEN-X, a biopharmaceutical company based in The Netherlands and focused on human monoclonal antibodies from its proprietary SIMPLE Antibody platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey.

More... »

Prezista receives E.C. approval for young children with HIV-1 infection

Friday, October 26, 2012 10:46 AM

The European Commission (E.C.) has approved Janssen/Cilag International’s 100mg/ml oral suspension of Prezista (darunavir), and the use of darunavir co-administered with low dose ritonavir, for the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral therapy (ART)-experienced pediatric patients age three and above, weighing at least 15kg. The drug must be taken in combination with other ARTs.

More... »

Synteract upgrades safety database systems to Oracle Argus

Friday, October 26, 2012 10:24 AM

Synteract, a full service CRO based in Carlsbad, Calif., has implemented two Oracle Argus 7.0 modules to its pharmacovigilance technology platform, Oracle Argus Safety and Oracle Argus Interchange.

More... »

Novelos enrolls first patient in solid tumor imaging trial

Thursday, October 25, 2012 09:48 AM

Novelos Therapeutics, a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, announced that the University of Wisconsin Carbone Cancer Center (UWCCC), an oncology research institution, has enrolled the first patient in a phase I/II positron emission tomography (PET) imaging trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging agent, in patients with nine solid tumor types, including triple negative breast, soft tissue sarcoma, colorectal, gastric, head and neck cancer, esophageal, prostate, ovarian and pancreatic.

More... »

Aclaris raises $21M in Series A Financing

Thursday, October 25, 2012 07:30 AM

Aclaris Therapeutics, a privately held specialty pharmaceutical company focused on dermatological therapeutics, has secured $21 million in Series A financing.

More... »